Pixel Tracker

Monday, February 18 , 2019, 6:39 am | Fair 43º

 
 
 
 

Sansum Diabetes Research Institute Conducts Landmark Clinic Trial

Five participants each supported by an artificial pancreas test their freedoms in a semi-outpatient environment

The Sansum Diabetes Research Institute is pleased to announce that a historical event for the treatment and cure of diabetes occurred this week at its research center in Santa Barbara, with a groundbreaking, 45-hour medical research study on the artificial pancreas.

The clinical trial began Monday and ended Wednesday. This significant milestone study was the largest in the United States, featuring five diabetes mellitus patients (deemed the “Fantastic Five” for their willingness to participate) who are supported by the AP in a semi-outpatient environment.

For the first time, the patients, not the researchers, were in control of this medical device, which runs automatically, reacting and delivering precise amounts of insulin when the body needs it, exactly like a normal human pancreas. Clinical trial participants were able to move about freely outside the confines of the research setting for short periods of time.

This research was part of a major collaborative effort funded by the Juvenile Diabetes Research Foundation focused on developing the artificial pancreas. Research partners for this study were UC Santa Barbara’s Chemical Engineering Department/Center for BioEngineering and the University of Virginia Center for Diabetes Technology.

In observing the trial patients, Dr. Lois Jovanovič, chief scientific officer at the Sansum Diabetes Research Institute, said, “It’s stunning to see the changes, the transformations these patients experience, while using the AP. They are no longer tethered to uncomfortable instrumentation, such as IV poles and medical devices, and are no longer confined to our inpatient setting. The AP components are held inside a small fanny pack that goes around the subjects’ waists. The ‘Fantastic Five’ are at liberty to attend to activities associated with daily living. You can plainly see they are more comfortable and confident about managing their diabetes; their blood sugar control and insulin levels are automatically ‘managed by machine.’ This trial is significant because it means we have turned the corner on diabetes mellitus treatment by making strides to restore people with diabetes to a normal, active lifestyle with improved management of their condition.”

According to Dr. Howard Zisser, director of clinical research and technology at Sansum Diabetes, “The device automates insulin delivery for people with Type 1 diabetes. It consists of a continuous glucose sensor, an insulin pump and a controller that decides in real-time how much insulin to deliver. Our trial is exceeding our expectations. It’s exciting to see patients operating the systems themselves as we monitor them remotely from the lab. They are not confined to the test laboratory; they have the liberty to move around our three-story facility and even take a walk outside.”

He added: “Another milestone will hopefully be the approval of a low glucose suspend system that will automatically stop insulin for short periods if someone’s glucose is low and they don’t respond to alarms. This system is widely available outside the United States.”

— Sarah Ettman-Sterner is the director of communications for the Sansum Diabetes Research Institute.

Talk to Us!

Please take Noozhawk's audience survey to help us understand what you expect — and want — from us. It'll take you just a few minutes. Thank you!

Get Started >

Support Noozhawk Today

You are an important ally in our mission to deliver clear, objective, high-quality professional news reporting for Santa Barbara, Goleta and the rest of Santa Barbara County. Join the Hawks Club today to help keep Noozhawk soaring.

We offer four membership levels: $5 a month, $10 a month, $25 a month or $1 a week. Payments can be made using a credit card, Apple Pay or Google Pay, or click here for information on recurring credit-card payments and a mailing address for checks.

Thank you for your vital support.

Become a Noozhawk Supporter

First name
Last name
Email
Select your monthly membership
Or choose an annual membership
×

Payment Information

Membership Subscription

You are enrolling in . Thank you for joining the Hawks Club.

Payment Method

Pay by Credit Card:

Mastercard, Visa, American Express, Discover
One click only, please!

Pay with Apple Pay or Google Pay:

Noozhawk partners with Stripe to provide secure invoicing and payments processing.
You may cancel your membership at any time by sending an email to .(JavaScript must be enabled to view this email address).

  • Ask
  • Vote
  • Investigate
  • Answer

Noozhawk Asks: What’s Your Question?

Welcome to Noozhawk Asks, a new feature in which you ask the questions, you help decide what Noozhawk investigates, and you work with us to find the answers.

Here’s how it works: You share your questions with us in the nearby box. In some cases, we may work with you to find the answers. In others, we may ask you to vote on your top choices to help us narrow the scope. And we’ll be regularly asking you for your feedback on a specific issue or topic.

We also expect to work together with the reader who asked the winning questions to find the answer together. Noozhawk’s objective is to come at questions from a place of curiosity and openness, and we believe a transparent collaboration is the key to achieve it.

The results of our investigation will be published here in this Noozhawk Asks section. Once or twice a month, we plan to do a review of what was asked and answered.

Thanks for asking!

Click Here to Get Started >

Reader Comments

Noozhawk is no longer accepting reader comments on our articles. Click here for the announcement. Readers are instead invited to submit letters to the editor by emailing them to [email protected]. Please provide your full name and community, as well as contact information for verification purposes only.

Daily Noozhawk

Subscribe to Noozhawk's A.M. Report, our free e-Bulletin sent out every day at 4:15 a.m. with Noozhawk's top stories, hand-picked by the editors.

Sign Up Now >